

# Use of Local Anesthesia for Pediatric Dental Patients

## Latest Revision

2023

**How to Cite:** American Academy of Pediatric Dentistry. Use of local anesthesia for pediatric dental patients. The Reference Manual of Pediatric Dentistry. Chicago, Ill.: American Academy of Pediatric Dentistry; 2024:386-93.

### Abstract

*This best practice presents recommendations regarding use of local anesthesia to control pain for pediatric dental patients. Considerations in the use of topical and local anesthetics include: the patient's medical history, developmental status, age, and weight; planned procedures; needle selection; and safety concerns such as risk for methemoglobinemia and systemic effects of anesthetic agents. Guidance is offered on the documentation of local anesthesia administration including anesthetic selection, dose administered, injection type and location, and postoperative instructions. Potential complications such as toxicity, paresthesia, allergy, and postoperative self-induced soft tissue injury are discussed. Additional recommendations address alternative methods of local anesthesia delivery, concurrent use with sedation or general anesthesia, and use during pregnancy. Pain management is an important component of oral health care and can result in a more positive patient experience during pediatric dental procedures.*

*This document was developed through a collaborative effort of the American Academy of Pediatric Dentistry Councils on Clinical Affairs and Scientific Affairs to offer updated information and recommendations on using local anesthetics in the management of dental pain for pediatric patients and persons with special health care needs.*

KEYWORDS: ANALGESICS; ANESTHESIA, GENERAL; ANESTHESIA, LOCAL; DELIVERY OF HEALTH CARE; METHEMOGLOBINEMIA; PAIN MANAGEMENT; PEDIATRIC DENTISTRY

### Purpose

The American Academy of Pediatric Dentistry (AAPD) intends this document to help practitioners make decisions regarding use of local anesthesia to control pain in infants, children, adolescents, and individuals with special health care needs during the delivery of oral health care.

### Methods

Recommendations on use of local anesthesia were developed by the Council on Clinical Affairs, adopted in 2005<sup>1</sup>, and last revised in 2020.<sup>2</sup> This update is based upon a literature search of the PubMed®/MEDLINE database using the terms: local anesthesia AND dentistry AND systematic review, topical anesthesia AND dentistry, buffered anesthesia AND dentistry. Two hundred forty-eight articles matched these criteria. Additionally, *Handbook of Local Anesthesia, 7th Edition*<sup>3</sup> contributed significantly to this revision. When data did not appear sufficient or were inconclusive, recommendations were based upon expert and/or consensus opinion by experienced researchers and clinicians.

### Background

Local anesthesia is the temporary loss of sensation in one part of the body produced by a topically-applied or injected agent. Local anesthetics act within neural fibers to inhibit the rapid ionic influx of sodium necessary for neuron impulse generation and propagation.<sup>4,5</sup> This helps prevent sensation of pain during procedures, which can foster a trusting relationship between

the patient and dentist, allay fear and anxiety, and promote a positive dental attitude. Inadequate pain control during dental procedures has the potential for significant physical and psychological consequences.<sup>6</sup> Many local anesthetic agents are available to facilitate management of pain in the dental patient. The two general types of local anesthetic chemical formulations are: (1) esters (e.g., procaine, benzocaine, tetracaine) and (2) amides (e.g., lidocaine, mepivacaine, prilocaine, articaine).<sup>7</sup>

The technique of local anesthetic administration is an important consideration in pediatric patient behavior guidance.<sup>8,9</sup> Age-appropriate nonthreatening terminology, distraction, topical anesthetics, proper injection technique, and pharmacologic management can help the patient have a positive experience during administration of local anesthetics.<sup>8,10(pg184)</sup> In pediatric dentistry, appropriate dosage (based on body weight) will minimize the chance of toxicity.<sup>11(pg294)</sup> Knowledge of gross and neuroanatomy of the head and neck allows for proper placement of the anesthetic solution and helps minimize complications (e.g., hematoma, trismus, intravascular injection).<sup>12(pg308)</sup> A comprehensive understanding of the patient's

### ABBREVIATIONS

**AAPD:** American Academy of Pediatric Dentistry. **ADA:** American Dental Association. **CNS:** Central nervous system. **FDA:** United States Food and Drug Administration. **kg:** Kilogram. **LAST:** Local anesthetic systemic toxicity. **mg:** Milligram. **mm:** Millimeter. **PDL:** Periodontal ligament.

medical history will decrease the risk of aggravating a medical condition while rendering dental care. A medical consultation may be indicated to obtain needed information.

### Topical anesthetics

The application of a topical anesthetic may help minimize discomfort caused during administration of local anesthesia. Single drugs which are often used as topical anesthetics in dentistry include 20 percent benzocaine, five percent lidocaine, and four percent tetracaine.<sup>13(pg79)</sup> Topical anesthetics are effective on surface tissues (up to two to three millimeters [mm] in depth) to reduce pain from needle penetration of the oral mucosa.<sup>13(pg76)</sup> These agents are available in gel, liquid, ointment, patch, and aerosol forms. The concentration of local anesthetics typically is higher in topical formulations than in injectable solutions, and judicious application will reduce potential for toxicity.<sup>13(pg76)</sup> Benzocaine and prilocaine both have been associated with a risk of acquired methemoglobinemia, and their use is contraindicated in patients with a history of methemoglobinemia.<sup>13(pg69),14,15(pg169)</sup> Acquired methemoglobinemia is a serious but rare condition that occurs when the ferrous iron in the hemoglobin molecule is oxidized to the ferric state. This molecule is known as methemoglobin, which is incapable of carrying oxygen and results in a decreased availability of oxygen to the tissues.<sup>14</sup> Prilocaine is also relatively contraindicated in patients at risk for methemoglobinemia (e.g., patients with glucose-6-phosphate dehydrogenase deficiency, sickle cell anemia, anemia; very young patients) or patients with symptoms of hypoxia.<sup>13(pg71),16</sup> Highly significant clinical concerns have been reported in patients receiving the combination of prilocaine-containing topical agents and methemoglobin-inducing agents (e.g., sulfonamides, acetaminophen, phenytoin).<sup>16</sup> Additionally, the United States Food and Drug Administration (FDA) warns against use of topical anesthetics (including over-the-counter teething products) containing benzocaine for children younger than two years.<sup>17</sup>

The FDA also has issued warnings about the potential toxicity of compounded topical anesthetics due to the high concentration of individual anesthetic components.<sup>18</sup> Compounded topical anesthetics are custom-made medications that may bypass the FDA's drug approval process. Use of compounded topical anesthetics with unknown concentrations of local anesthetics carries a

risk of complications associated with overdose, including seizures, arrhythmias, and death.<sup>18</sup>

### Selection of syringes and needles

The American Dental Association (ADA) has standards for aspirating syringes for use in the administration of local anesthesia.<sup>19,20</sup> Needle gauges range from size 23 to 30, with the lower numbers having the larger inner diameter. Needles with lower gauge number (larger diameter) provide for less deflection as the needle passes through soft tissues and for more reliable aspiration.<sup>21(pg101)</sup> The depth of insertion varies not only by injection technique but also by the age and size of the patient. Dental needles are available in three lengths: long (32 mm), short (20 mm), and ultrashort (10 mm). Most needle fractures occur during the administration of inferior alveolar nerve block with 30-gauge needles.<sup>22</sup> Breakage can occur when a needle is inserted to the hub<sup>21(pg100)</sup>, when the needle is weakened due to bending before insertion into the soft tissues, or by patient movement after the needle is inserted.<sup>12(pg309),22,23</sup>

### Injectable local anesthetic agents (Table)

Amide local anesthetics available for dental usage include lidocaine, mepivacaine, articaine, prilocaine, and bupivacaine. Agents that include epinephrine are formulated to an approximate pH of 4.5 in order to prolong the shelf life of the vasoconstrictor, but this may activate acid-sensing nociceptors

Table. INJECTABLE LOCAL ANESTHETICS (Adapted from Coté CJ et al. <sup>24</sup> *)				
Anesthetic	Duration in minutes <sup>A</sup>	Maximum dose <sup>B</sup>		mg vasoconstrictor/ 1.7 mL cartridge
		mg/kg	mg/lb	
<i>Lidocaine</i> <sup>C</sup>	90-200	4.4	2	
2%+1:50,000 epinephrine				34
2%+1:100,000 epinephrine				34
<i>Articaine</i> <sup>D</sup>	60-230	7	3.2	
4%+1:100,000 epinephrine				68
4%+1:200,000 epinephrine				68
<i>Mepivacaine</i>	120-240	4.4	2	
3% plain				51
2%+1:200,000 levonordefrin				34
<i>Bupivacaine</i> <sup>E</sup>	180-600	1.3	0.6	
0.5%+1:200,000 epinephrine				8.5

\* Abbreviations used in this table: kg=kilogram; lb=pound; mg=milligram; mL=milliliter.

<sup>A</sup> Duration of anesthesia varies greatly depending on concentration, total dose, and site of administration; use of epinephrine; and the patient's age.

<sup>B</sup> Use lowest total dose that provides effective anesthesia. Lower doses should be used in very vascular areas or when providing local anesthesia without vasoconstrictor. Doses of amides should be decreased by 30 percent in infants younger than six months. For improved safety, AAPD, in conjunction with the American Academy of Pediatrics, recommends a dosing schedule for dental procedures that is more conservative than the manufacturer's recommended dose (MRD).

<sup>C</sup> The table lists the long-established pediatric dental maximum dose of lidocaine as 4.4 mg/kg; however, the MRD is 7 mg/kg.

<sup>D</sup> Use in pediatric patients under four years of age is not recommended.

<sup>E</sup> Use in patients under 12 years of age is not recommended.<sup>25</sup>

and lead to increased pain.<sup>26</sup> The higher acidity of local anesthetics with vasoconstrictor also may slow the onset of the anesthetic while it transforms from its ionized to non-ionized form in order to penetrate the lipid membrane of the nerve sheath.<sup>26</sup> In dentistry, the effect of adjusting the pH of local anesthetics with epinephrine is of interest as a way to reduce pain and time to onset of anesthesia. One systematic review found that local anesthetic with epinephrine buffered with sodium bicarbonate was 2.3 times more likely to achieve anesthesia than nonbuffered agents for participants with a clinical diagnosis of symptomatic irreversible pulpitis requiring endodontic treatment.<sup>27</sup> Another systematic review found that the pH adjustment was not effective in reducing pain of intraoral injections, but buffering did reduce the time to onset of anesthesia when performing inferior alveolar nerve blocks or injecting into inflamed tissues.<sup>26</sup> This review concluded that the reduced time may not be clinically relevant considering the time required to prepare the buffered agent.<sup>26</sup> Similar results were found in children ages six to 12 years old.<sup>28</sup> Additional research is needed regarding the effect of buffered local anesthetic on pain reduction in children.<sup>28,29</sup>

Vasoconstrictors (e.g., epinephrine, levonordefrin, norepinephrine) are added to local anesthetics to constrict blood vessels in the area of injection. This lowers the rate of absorption of the local anesthetic into the blood stream, thereby lowering the risk of toxicity and prolonging the anesthetic action in the area.<sup>30</sup> For patients with hyperthyroidism, cautious use of epinephrine as a vasoconstrictor in local anesthetics is warranted to decrease risk of tachycardia or hypertension.<sup>15(pg148)</sup> Patients with significant cardiovascular disease<sup>15(pg144)</sup>, thyroid dysfunction<sup>15(pg148)</sup>, diabetes<sup>15(pg148)</sup>, or sulfite sensitivity<sup>31(pg349)</sup> and those receiving monoamine oxidase inhibitors<sup>15(pg166)</sup>, tricyclic antidepressants<sup>15(pg164)</sup>, antipsychotic drugs<sup>15(pg165)</sup>, norepinephrine, or phenothiazines<sup>15(pp165,166)</sup> may require a medical consultation to determine the need for a local anesthetic without vasoconstrictor.<sup>15(pg149)</sup> The Malignant Hyperthermia Association of the United States indicates that all local anesthetics, including those with vasoconstrictor, are safe for use in patients susceptible to malignant hyperthermia.<sup>32,33</sup> When halogenated gases are used for general anesthesia, however, the myocardium is sensitized to epinephrine, and such situations dictate caution with use of a local anesthetic.<sup>15(pg165)</sup> As with the topical form, injectable prilocaine is relatively contraindicated in patients with susceptibility to methemoglobinemia.<sup>13(pg71)</sup> While the prolonged effect of a long-acting local anesthetic (i.e., bupivacaine) can be beneficial for postoperative pain in adults, the concomitant increased risk of self-inflicted injury infers that it is contraindicated for children or intellectually disabled patients.<sup>11(pg298)</sup>

The mandibular cortical bone of a child is less dense than that of an adult, permitting more rapid and complete diffusion of the injected anesthetic.<sup>11(pg297)</sup> Because of this increased permeability, mandibular buccal supraperiosteal infiltration with local anesthetic may be as effective as an inferior alveolar nerve block for dental procedures (e.g., intracoronary restorations) on

mandibular primary teeth.<sup>11(pg298)</sup> Multiple systematic reviews have compared inferior alveolar nerve blocks with lidocaine to infiltration with articaine for restorative treatment, pulp therapy, and extractions of both primary and permanent molars in individuals under 18 years of age<sup>34-39</sup>; the evidence regarding superiority is inconclusive. The ability of articaine to diffuse through hard and soft tissue from a buccal infiltration to provide lingual or palatal soft tissue anesthesia has been reported as a potential advantage over lidocaine.<sup>13(pg73),40</sup>

If a local anesthetic is injected into an area of infection, its time to onset may be prolonged or anesthesia may be ineffective.<sup>11(pg289)</sup> Infection lowers the pH of the extracellular tissue, inhibiting diffusion of the active free base form of the anesthetic across the neural membrane, thereby stopping nerve impulse conduction.<sup>11(pg289)</sup> Endocarditis prophylaxis (antibiotics) is not recommended for routine local anesthetic injections through noninfected tissue in patients considered at risk.<sup>41</sup>

### Documentation of local anesthesia

The patient record is an essential component of the delivery of competent and quality oral health care.<sup>42</sup> Following each appointment, an entry is made in the record that accurately and objectively summarizes that visit. Appropriate documentation includes specific information relative to the administration of local anesthetics. This would include, at a minimum, the type and dosage of local anesthetic administered.<sup>42</sup> Documentation also may include the type of injection(s) administered (e.g., infiltration, block, intraosseous), needle selection, and patient's reaction to the injection. For example, local anesthetic administration might be recorded as: mandibular block with 27-short; 34 milligrams (mg) two percent lidocaine with 0.017 mg epinephrine (or 1/100,000 epinephrine); tolerated procedure well. With patients for whom the maximum dosage of local anesthetic may be a concern (e.g., young patients, those undergoing sedation), documenting the body weight and calculating the maximum recommended total dose preoperatively can help prevent overdosage. Because there may be enhanced sedative effects when local anesthetics are administered in conjunction with sedative drugs, recording doses of all agents on a time-based record can help ensure patient safety.<sup>24</sup> Local anesthesia documentation also includes a statement that post-injection instructions were reviewed with the patient and parent.

### Local anesthetic complications

Critical to the safety of all patients during the administration of local anesthetics are the practitioner's awareness of the risks for complications and efforts to prevent them, recognition of the signs and symptoms of an adverse event, and the ability to provide time-critical interventions in case of a medical emergency.

### Local anesthetic systemic toxicity (LAST; overdose)

Younger pediatric patients are at greater risk for adverse drug events.<sup>31(pg332)</sup> Most adverse drug reactions develop either during the injection or within five to 10 minutes.<sup>43</sup> LAST can result

from high blood levels caused by a single inadvertent intravascular injection or repeated injections.<sup>31(pg334)</sup> Local anesthetic causes a biphasic reaction (excitation followed by depression) in the central nervous system (CNS).<sup>44(pg32)</sup> The classic overdose reaction to local anesthetic is generalized tonic-clonic convulsion.<sup>44(pg33)</sup> Early subjective indications of toxicity involve the CNS and include dizziness, anxiety, and confusion. This may be followed by diplopia, tinnitus, drowsiness, and circumoral numbness or tingling. Objective signs may include muscle twitching, tremors, talkativeness, slowed speech, and shivering, followed by overt seizure activity. Loss of consciousness and respiratory arrest may occur.<sup>7</sup>

The cardiovascular system response to local anesthetic toxicity also is biphasic. Initially, heart rate and blood pressure may increase due to the injected epinephrine. As plasma levels of the anesthetic increase, however, vasodilatation occurs followed by depression of the myocardium and a subsequent fall in blood pressure. Local anesthetics block voltage-gated sodium channels that are responsible for the generation of cardiac arrhythmias, and overdose may cause bradycardia and subsequent cardiac arrest. The cardiodepressant effects of local anesthetics are not seen until there is a significantly elevated level in the blood.<sup>31(pg342)</sup>

LAST can be prevented by careful injection technique, watchful observation of the patient, and knowledge of the maximum dosage based on body weight. This would include aspirating after needle placement before agent delivery during every injection and injecting slowly.<sup>10(pg181)</sup> Aspiration decreases the risk of an intravascular injection, and a slow injection technique reduces tissue distortion and related discomfort. After the injection, the clinical observation of the patient will enable early recognition of a toxic response. When signs or symptoms of toxicity are noted, administration of the local anesthetic agent is discontinued and additional emergency management, including patient rescue and activation of emergency medical services, is based on the severity of the reaction.<sup>5</sup> Early treatment with intravenous lipid emulsion therapy is a priority in potentially serious cases of LAST.<sup>45</sup>

### **Allergy to local anesthetics**

Allergy to a local anesthetic, a rare finding, is an absolute contraindication for its use.<sup>13(pg81)</sup> Allergy to one amide does not rule out the use of another amide, but allergy to one ester rules out use of another ester.<sup>31(pg347)</sup> Patients may report an allergy to local anesthetic agents even though they experienced a reaction to the vasoconstrictor, a sensitivity to a preservative (metabisulfite) in agents containing epinephrine, administration of a toxic dose, or an intravascular injection. Documentation of the previous event and/or allergy testing can help the practitioner proceed with procedural pain management. For patients having an allergy to bisulfites, use of a local anesthetic without vasoconstrictor is indicated.<sup>31(pg349)</sup> Allergic reactions are not dose related but are due to the patient's heightened capacity to react to even a small dose and can manifest in a variety of ways, some of which include urticaria, dermatitis,

angioedema, fever, photosensitivity, or anaphylaxis.<sup>31(pg354)</sup> Emergency management is dependent on the rate and severity of the reaction.

### **Paresthesia**

Paresthesia is persistent anesthesia beyond the expected duration. Trauma to the nerve can result in paresthesia and, among other etiologies, can be caused by the needle during the injection.<sup>12(pg310)</sup> Patients who initially experience an electric shock sensation during injection may have persistent anesthesia.<sup>12(pg312)</sup> Paresthesia has been reported to be more common with four percent solutions such as articaine and prilocaine compared to those of lower concentrations.<sup>46,47</sup>

### **Postoperative soft tissue injury**

Self-induced soft tissue trauma (e.g., lip and cheek biting) is an unfortunate clinical complication of local anesthetic use in the oral cavity. Most lesions of this nature are self-limiting and heal without complications, although bleeding and infection are possible.<sup>12(pg320)</sup> The use of bilateral mandibular blocks may increase the risk of soft tissue trauma when compared to unilateral mandibular blocks or ipsilateral maxillary infiltration.<sup>48</sup>

Advising the patient/caregiver of a realistic duration of numbness and postoperative precautions is necessary to decrease the risk of self-induced soft tissue trauma. Visual examples may help stress the importance of observation during the period of numbness. For all local anesthetics, the duration of soft tissue anesthesia is greater than dentinal or osseous anesthesia. Use of phentolamine mesylate injections in patients over age six years or at least 15 kilograms (kg) has been shown to reduce the duration of effects of local anesthetic by about 47 percent in the maxilla and 67 percent in the mandible.<sup>49,50</sup> Phentolamine mesylate reverses the vasoconstrictor via its antagonistic effect at the  $\alpha_1$  receptor, allowing for vasodilation and rapid metabolism of local anesthetic.<sup>50</sup> A relationship between reduction in soft tissue trauma and the use of shorter acting local anesthetics has not been demonstrated.<sup>11(pg296)</sup> Use of phentolamine mesylate is not recommended for patients who are younger than three years of age or weigh less than 15 kg (33 pounds).<sup>51</sup>

### **Alternative techniques for delivery of local anesthesia**

Most local anesthesia procedures in pediatric dentistry involve traditional methods of infiltration or nerve block techniques with a dental syringe, disposable cartridges, and needles as described so far. Several alternative techniques, including computer-controlled local anesthetic delivery, periodontal injection techniques, needleless systems, and intraseptal or intrapulpal injection, are available. Such techniques may improve comfort of injection by better control of the administration rate, pressure, and location of anesthetic solutions and result in more successful and controlled anesthesia.<sup>52</sup>

In patients with bleeding disorders, the periodontal ligament (PDL) injection minimizes the potential for postoperative bleeding of soft tissue vessels.<sup>15(pg142)</sup> The use of the PDL

injection or intraosseous methods is contraindicated in the presence of inflammation or infection at the injection site.<sup>53</sup>

### Local anesthesia with sedation and general anesthesia

Local anesthetics and sedative agents both depress the CNS. Therefore, it is recommended that the dose of local anesthetic be adjusted downward when sedating children with opioids.<sup>54</sup>

Reasons to use local anesthesia for dental procedures under general anesthesia include concerns for increased future pain sensitivity due to CNS priming<sup>55</sup> and reduction in postoperative pain. In patients undergoing general anesthesia for dental treatment including restorations and extractions, however, the evidence for administration of local anesthesia intraoperatively to reduce postoperative pain is equivocal.<sup>56,57</sup> Furthermore, intraoperative use of local anesthesia may increase risk of postoperative soft tissue trauma while the patient is numb.<sup>58</sup>

### Local anesthesia and pregnancy

Pregnancy causes many physiologic changes, including effects on cardiovascular function and metabolism.<sup>59</sup> Consideration should be given to the risks and benefits of dental treatment to the pregnant patient and fetus when choosing therapeutics.<sup>60</sup> Local anesthetics, including lidocaine, mepivacaine, and bupivacaine, are safe for pregnant patients when the appropriate dosage is used.<sup>61</sup> Because local anesthetics can pass through the placental barrier, additional caution is indicated when the fetus has known medical complications.<sup>59</sup> Epinephrine may cause contraction of uterine blood vessels and limit blood flow to the placenta.<sup>59</sup> Therefore, caution is indicated in the use of local anesthetics with vasoconstrictor for pregnant women, particularly those with hypertensive conditions (e.g., preeclampsia).<sup>59</sup> The second trimester of pregnancy, when organogenesis of the fetus is complete and comfortable positioning in the dental chair may still be possible, may be the optimal time to complete non-urgent dental treatment.<sup>60</sup> Lidocaine is considered safe for use during breastfeeding.<sup>62,63</sup>

### Recommendations

Local anesthesia is an important consideration in behavior guidance of pediatric dental patients. Inadequate pain control during dental procedures has the potential for significant physical and psychological consequences, including altering future pain experiences for these children.<sup>6</sup> Agents used for prevention of pediatric procedural pain have the potential for toxicity and adverse reactions. Practitioners should adhere to the following recommendations for use of local anesthetics for pediatric dental patients.

1. Selection of local anesthetic agents should be based on the patient's medical history and mental/developmental status, the anticipated duration of the dental procedure, and the planned administration of other agents (e.g., nitrous oxide, sedative agents, general anesthesia).
2. Administration of local anesthetic should be based on the body weight of the patient, not to exceed AAPD

recommendations in mg/kg found in Table. Practitioners should use the lowest total dose that provides effective anesthesia.

3. A topical anesthetic may be used prior to the injection of a local anesthetic to reduce discomfort associated with needle penetration. Systemic absorption of the drugs in topical anesthetics must be considered when calculating the total amount of anesthetic administered.
4. Documentation of local anesthetic administration should include, at a minimum, the type and dosage of agent. If the local anesthetic was administered in conjunction with sedative drugs, the doses of all agents must be noted on a time-based record.
5. The calculated maximum total dose for local anesthetics should be reduced when administered in conjunction with other medications that depress the CNS.
6. The calculated maximum total dose of amide local anesthetics should be reduced by 30 percent in infants younger than six months.<sup>24</sup>
7. Postoperative instructions should include guidance regarding the duration of local anesthesia and strategies to reduce the risk of biting the lip, cheek, or tongue.
8. Providers should have protocols for emergency management of patients exhibiting signs of LAST or an allergic reaction.

### Additional safety considerations

Careful selection, dosage, and technique are critical to the safe administration of local anesthetics for pediatric patients. Important considerations include:

1. In the Table, the long-established maximum safe dose for use of lidocaine with pediatric dental patients is 4.4 mg/kg; however, seven mg/kg is the manufacturer's recommended maximum dose. The maximum dose for articaine as recommended by the manufacturer is seven mg/kg. The lowest total dose that provides effective anesthesia should be used, and lower total doses should be used for injections into vascular areas. For improved safety, AAPD, in conjunction with the American Academy of Pediatrics, recommends a dosing schedule for dental procedures that is more conservative than the manufacturer's recommended dose.
2. Manufacturers do not recommend articaine use in pediatric dental patients younger than four years. The use of bupivacaine is not recommended in patients younger than 12 years.
3. Compounded topical anesthetics may contain very high combined levels of both amide and ester agents which can lead to serious adverse reactions.
4. Use of benzocaine is contraindicated in patients with a history of methemoglobinemia and in children

younger than two years of age. Prilocaine is also contraindicated in patients with a history of methemoglobinemia and relatively contraindicated in those who are susceptible to methemoglobinemia due to medical history or concurrent use of other medications.

5. Needles are prone to breakage if bent prior to injection or inserted to their hub.
6. Aspiration prior to injection and slow injection technique reduce the risk of adverse events related to systemic administration of the local anesthetic.

## References

1. American Academy of Pediatric Dentistry. Appropriate use of local anesthesia for pediatric dental patients. *Pediatr Dent* 2005;27(Suppl):101-6.
2. American Academy of Pediatric Dentistry. Use of local anesthesia for pediatric dental patients. *The Reference Manual of Pediatric Dentistry*. Chicago, Ill.: American Academy of Pediatric Dentistry; 2020:318-23.
3. Malamed SF. *Handbook of Local Anesthesia*. 7th ed. St. Louis, Mo.: Mosby; 2020.
4. Malamed SF. Neurophysiology. In: *Handbook of Local Anesthesia*. 7th ed. St. Louis, Mo.: Mosby; 2020:14.
5. Ogle OE, Mahjoubi G. Local anesthesia: Agents, techniques, and complications. *Dent Clin North Am* 2012; 56(1):133-48.
6. American Academy of Pediatric Dentistry. Pain management in infants, children, adolescents, and individuals with special health care needs. *The Reference Manual of Pediatric Dentistry*. Chicago, Ill.: American Academy of Pediatric Dentistry; 2023:434-42.
7. Moore PA, Hersh EV. Local anesthetics: Pharmacology and toxicity. *Dent Clin North Am* 2010;54(4):587-99.
8. Gosnell ES, Thikkurissy S. Assessment and management of pain in the pediatric patient. In: Nowak AJ, Christensen JR, Mabry TR, Townsend JA, Wells MH, eds. *Pediatric Dentistry Infancy Through Adolescence*. 6th ed. Philadelphia, Pa.: Elsevier; 2019:110.
9. Jones JE, Scully AC. Local anesthesia and pain control for the child and adolescent. In: Dean JA, ed. *McDonald and Avery's Dentistry for the Child and Adolescent*. 11th ed. St. Louis, Mo.: Elsevier; 2022:327.
10. Malamed SF. Basic injection technique. In: *Handbook of Local Anesthesia*. 7th ed. St. Louis, Mo.: Mosby; 2020: 173-85.
11. Malamed SF. Anesthetic considerations in dental specialties. In: *Handbook of Local Anesthesia*. 7th ed. St. Louis, Mo.: Mosby; 2020:289-307.
12. Malamed SF. Local complications. In: *Handbook of Local Anesthesia*. 7th ed. St. Louis, Mo.: Mosby; 2020:308-29.
13. Malamed SF. Clinical action of specific agents. In: *Handbook of Local Anesthesia*. 7th ed. St. Louis, Mo.: Mosby; 2020:57-85.
14. Gutenberg LL, Chen JW, Trapp L. Methemoglobin levels in generally anesthetized pediatric dental patients receiving prilocaine versus lidocaine. *Anesth Prog* 2013;60(3): 99-108.
15. Malamed SF. Physical and psychological evaluation. In: *Handbook of Local Anesthesia*. 7th ed. St. Louis, Mo.: Mosby; 2020:134-72.
16. Drugs.com. EMLA prescribing information; c1996-2018. Updated April 21, 2023. Available at: "<https://www.drugs.com/pro/emla.html>". Accessed May 30, 2023.
17. U.S. Food and Drug Administration. Risk of serious and potentially fatal blood disorder prompts FDA action on oral over-the-counter benzocaine products used for teething and mouth pain and prescription local anesthetics. May 31, 2018. Available at: "<https://www.fda.gov/drugs/drug-safety-and-availability/risk-serious-and-potentially-fatal-blood-disorder-prompts-fda-action-oral-over-counter-benzocaine>". Accessed January 26, 2023.
18. Kravitz ND. The use of compound topical anesthetics: A review. *J Am Dent Assoc* 2007;138(10):1333-9.
19. American Dental Association Council on Dental Materials and Devices. New American National Standards Institute/American Dental Association specification no. 34 for dental aspirating syringes. *J Am Dent Assoc* 1978;97(2): 236-8.
20. American Dental Association Council on Dental Materials, Instruments, and Equipment. Addendum to American National Standards Institute/American Dental Association Specification No. 34 for dental aspirating syringes. *J Am Dent Assoc* 1982;104(1):69-70.
21. Malamed SF. The needle. In: *Handbook of Local Anesthesia*. 7th ed. St. Louis, Mo.: Mosby; 2020:99-110.
22. Progel MA. Broken local anesthetic needles: A case series of 16 patients, with recommendations. *J Am Dent Assoc* 2009;140(12):1517-22.
23. Malamed SF, Reed KL, Poorsattar S. Needle breakage: Incidence and prevention. *Dent Clin North Am* 2010;54 (4):745-56.
24. Coté CJ, Wilson S. American Academy of Pediatric Dentistry, American Academy of Pediatrics. Guidelines for monitoring and management of pediatric patients before, during, and after sedation for diagnostic and therapeutic procedures. *Pediatrics* 2019;143(6):e20191000.
25. Hospira. Bupivacaine HCl. U.S. Food and Drug Administration. Available at: "[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2018/022046s009lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022046s009lbl.pdf)". Accessed March 17, 2023.
26. Aulestia-Viera PV, Braga MM, Borsatti MA. The effect of adjusting the pH of local anaesthetics in dentistry: A systematic review and meta-analysis. *Int Endod J* 2018; 51(8):862-76. Available at: "<https://onlinelibrary.wiley.com/doi/10.1111/iej.12899>". Accessed March 17, 2023.

*References continued on the next page.*

27. Kattan S, Lee S-M, Hersh EV, Karabucak B. Do buffered local anesthetics provide more successful anesthesia than non-buffered solutions in patients with pulpally involved teeth requiring dental therapy?: A systematic review. *J Am Dent Assoc* 2019;150(3):165-7.
28. Chopra R, Jindal G, Sachdev V, Sandhu M. Double-blind crossover study to compare pain experience during inferior alveolar nerve block administration using buffered two percent lidocaine in children. *Pediatr Dent* 2016;38(1):25-9.
29. Tirupathi SP, Rajasekhar S. Buffered versus unbuffered local anesthesia for inferior alveolar nerve block injections in children: A systematic review. *J Dent Anesth Pain Med* 2020;20(5):271-9.
30. Malamed SF. Pharmacology of vasoconstrictors. In: *Handbook of Local Anesthesia*. 7th ed. St. Louis, Mo.: Mosby; 2020:41.
31. Malamed SF. Systemic complications. In: *Handbook of Local Anesthesia*. 7th ed. St. Louis, Mo.: Mosby; 2020:330-60.
32. Malignant Hyperthermia Association of the United States. Lidocaine with epinephrine in MH susceptibility. Available at: "<https://www.mhaus.org/cfw/index.cfm?controller=kb&action=view-article&key=C907B4F2-5056-A852-6B3E-FC63DE717016&seoTitle=lidocaine-with-epinephrine-in-mh-susceptibility>". Accessed March 14, 2023.
33. Malignant Hyperthermia Association of the United States. Safe and unsafe anesthetics. Available at: "<https://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics/>". Accessed March 19, 2023.
34. Almadhoon HW, Abuiriban RW, Almassri H, Al-Hamed FS. Efficacy of 4% articaine buccal infiltration versus inferior alveolar nerve block for mandibular molars with symptomatic irreversible pulpitis: A systematic review and meta-analysis. *J Evid Based Dent Pract* 2022;22(2):101712.
35. de Geus JL, da Costa KN, Wambier LM, et al. Different anesthetics on the efficacy of inferior alveolar nerve block in patients with irreversible pulpitis. *J Am Dent Assoc* 2020;151(2):87-97.
36. Katyal V. The efficacy and safety of articaine versus lignocaine in dental treatment: A meta-analysis. *J Dent* 2010;38(4):307-17.
37. St. George G, Morgan A, Meechan J, et al. Injectable local anaesthetic agents for dental anaesthesia. *Cochrane Database Syst Rev* 2018;7(7):CD006487.
38. Tong HJ, Alzahrani FS, Sim YF, et al. Anaesthetic efficacy of articaine versus lidocaine in children's dentistry: A systematic review and meta-analysis. *Int J Paediatr Dent* 2018;28(4):347-60.
39. Yu J. Can buccal infiltration of articaine replace traditional inferior alveolar nerve block for the treatment of mandibular molars in pediatric patients?: A systematic review and meta-analysis. *Med Oral Pathol Oral Cir Bucal* 2021;26(6):e754-61.
40. Al-Mahalawy H, Abuhashish H, Chathoth S, Al-Masoud N, Al-Jandan B. Articaine versus lidocaine concentration in the palatal tissues after supraperiosteal buccal infiltration anesthesia. *J Oral Maxillofac Surg* 2018;76(2):315.e1-315.e7.
41. Wilson WR, Gewitz M, Lockhart PB, et al. Prevention of viridans group streptococcal infective endocarditis: A scientific statement from the American Heart Association. *Circulation* 2021;143(20):e963-e978. Erratum in: *Circulation* 2021;144(9):e192. Erratum in: *Circulation* 2022;145(17):e868. Available at: "<https://www.aha.org/journals/doi/10.1161/CIR.0000000000000969>". Accessed January 8, 2023.
42. American Academy of Pediatric Dentistry. Record-keeping. *The Reference Manual of Pediatric Dentistry*. Chicago, Ill.: American Academy of Pediatric Dentistry; 2023:564-71.
43. Long B, Chavez S, Gottlieb M, Montrieff T, Brady WJ. Local anesthetic systemic toxicity: A narrative review for emergency clinicians. *Am J Emerg Med* 2022;59:42-8.
44. Malamed SF. Pharmacology of local anesthetics. In: *Handbook of Local Anesthesia*. 7th ed. St. Louis, Mo.: Mosby; 2020:27-40.
45. El-Boghdadly K, Pawa A, Chin KJ. Local anesthetic systemic toxicity: Current perspectives. *Local Reg Anesth* 2018;11:35-44. Available at: "<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6087022/pdf/lra-11-035.pdf>". Accessed March 17, 2023.
46. Aquilanti L, Mascitti M, Togni L, Contaldo M, Rappelli G, Santarelli A. A systematic review on nerve-related adverse effects following mandibular nerve block anesthesia. *Int J Environ Res Public Health* 2022;19(3):1627.
47. Garisto GA, Gaffen AS, Lawrence HP, et al. Occurrence of paresthesia after dental local anesthetic administration in the United States. *J Am Dent Assoc* 2010;141(7):836-44.
48. Malamed SF. Techniques of mandibular anesthesia. In: *Handbook of Local Anesthesia*. 7th ed. St. Louis, Mo.: Mosby; 2020:240.
49. Hersh EV, Moore PA, Papas AS, et al. Reversal of soft tissue local anesthesia with phentolamine mesylate in adolescents and adults. *J Am Dent Assoc* 2008;139(8):1080-93.
50. Tavares M, Goodson MJ, Studen-Pavlovich D, et al. Reversal of soft-tissue local anesthesia with phentolamine mesylate in pediatric patients. *J Am Dent Assoc* 2008;139(8):1095-104.
51. Septodont. Oraverse. U.S. Food and Drug Administration. Available at: "[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2016/022159s011lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022159s011lbl.pdf)". Accessed Mar 17, 2023.

52. Clark TM, Yagiela JA. Advanced techniques and armamentarium for dental local anesthesia. *Dent Clin North Am* 2010;54(4):757-68.
53. Malamed SF. Supplemental injection techniques. In: *Handbook of Local Anesthesia*. 7th ed. St. Louis, Mo.: Mosby; 2020:269.
54. Becker DE, Reed KL. Local anesthetics: Review of pharmacological considerations. *Anesth Prog* 2012;59(2):90-101.
55. Baccei ML, Fitzgerald M. Development of pain pathways and mechanisms. In: McMahon SB, Koltzenburg M, Tracey I, Turk DC, eds. *Wall and Melzack's Textbook of Pain*, 6th ed. Philadelphia, Pa.: Elsevier Saunders; 2013:154.
56. Kaufman E, Epstein JB, Gorsky M, Jackson DL, Kadari A. Preemptive analgesia and local anesthesia as a supplement to general anesthesia: A review. *Anes Progress* 2005;52(1):29-38.
57. Moness Ali AM, Hammuda AA. Local anesthesia effects on postoperative pain after pediatric oral rehabilitation under general anesthesia. *Pediatr Dent* 2019;41(3):181-5.
58. Parekh S, Gardener C, Ashley PF, Walsh T. Intraoperative local anaesthesia for reduction of postoperative pain following general anaesthesia for dental treatment in children and adolescents. *Cochrane Database Syst Rev* 2014;(12):CD009742. Available at: "<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6669268/pdf/CD009742.pdf>". Accessed March 18, 2023.
59. Lee JM, Shin TJ. Use of local anesthetics for dental treatment during pregnancy; safety for parturient. *J Dent Anesth Pain Med* 2017;17(2):81-90.
60. American Academy of Pediatric Dentistry. Oral health care for the pregnant pediatric dental patient. *The Reference Manual of Pediatric Dentistry*. Chicago, Ill.: American Academy of Pediatric Dentistry; 2023:327-36.
61. Oral Health Care During Pregnancy Expert Workgroup. *Oral Health Care During Pregnancy: A National Summary of a Consensus Statement*. Washington, D.C.: National Maternal and Child Oral Health Resource Center; 2012. Available at: "<https://www.mchoralhealth.org/PDFs/OralHealthPregnancyConsensus.pdf>". Accessed March 7, 2023.
62. Favero V, Bacci C, Volpato A, et al. Pregnancy and dentistry: A literature review on risk management during dental surgical procedures. *Dent J (Basel)* 2021;9(4):46.
63. Drugs and Lactation Database (LactMed®) [Internet]. Lidocaine. Last Revision: November 16, 2020. Bethesda, Md.: National Institute of Child Health and Human Development; 2006. Available at: "<https://www.ncbi.nlm.nih.gov/books/NBK501230/>". Accessed May 30, 2023.